Skip to content
Bristows
Expertise
Core sectors
Life sciences
Technology
Brands
Litigation & dispute resolution (Archive)
Advertising & marketing
Arbitration
Artificial intelligence
Charities and not-for-profit
Commercial & IP transactions
Competition advice & investigations
Competition litigation
Corporate & financing
Cyber & data breaches
Transactions
Data protection & privacy
Defamation & privacy disputes
Employment & immigration
Freedom to operate
IT & digital projects
IT disputes
Life sciences regulatory
Litigation & dispute resolution
Merger control
Regulatory & advisory
Outsourcing
Patent litigation
Real estate
SEP/FRAND disputes
Tax
Telecommunications
Trade mark, designs & copyright disputes
Trade mark & design portfolio management
UPC
Viewpoint
Articles
Events
News
Podcasts
Publications
People
Careers
Apprentices
Current opportunities
Diversity, Equality & Inclusion
Life at Bristows
Trainees
About us
Alumni
A reputation for firsts
Awards
Compliance information
Corporate responsibility
GDPR
International horizon
Our locations
Our values
Contact
Search...
toggle mobile menu
Home
On the Pulse
On the Pulse
VIEW:
By topic
All topics
FSR
Firm news
In the press
Awards and accolades
Healthtech
Copyright
Artificial Intelligence
FRAND
UPC
Trade marks
Digital Single Market
Gene editing
Patents
Licensing
Employment / employers
Interactive entertainment
COVID-19
Brexit
Open Technology
By keyword
By sector
All sectors
Life sciences
Technology
Brands
By practice
All practices
Competition advice & investigations
Commercial disputes
Merger control
Trade mark, designs & copyright
Judicial review
Trade mark & design portfolio management
Commercial & IP transactions
Competition
Freedom to operate
Patent litigation
SEP/FRAND disputes
Life sciences regulatory
Brexit
IT & digital projects
Defamation & privacy disputes
Data protection & privacy
COVID-19
Real estate
IT disputes
Corporate & financing
Arbitration
Employment & immigration
Confidential information & trade secrets
Tax
Life sciences: contract & product liability disputes
Charities & not-for-profit
Telecommunications
Advertising & marketing
Outsourcing
Cyber & data breaches
Artificial intelligence
By date
All dates
July 2025
May 2025
April 2025
February 2025
January 2025
December 2024
November 2024
September 2024
August 2024
June 2024
May 2024
April 2024
February 2024
January 2024
December 2023
November 2023
October 2023
September 2023
August 2023
July 2023
June 2023
May 2023
April 2023
March 2023
February 2023
January 2023
December 2022
November 2022
October 2022
September 2022
August 2022
July 2022
June 2022
May 2022
April 2022
March 2022
February 2022
January 2022
December 2021
November 2021
October 2021
September 2021
August 2021
July 2021
June 2021
May 2021
April 2021
March 2021
February 2021
January 2021
December 2020
November 2020
October 2020
September 2020
August 2020
July 2020
June 2020
May 2020
April 2020
March 2020
February 2020
January 2020
December 2019
November 2019
October 2019
September 2019
August 2019
July 2019
June 2019
May 2019
April 2019
March 2019
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018
August 2018
July 2018
June 2018
May 2018
April 2018
March 2018
February 2018
January 2018
December 2017
November 2017
October 2017
September 2017
August 2017
July 2017
June 2017
May 2017
April 2017
March 2017
February 2017
January 2017
December 2016
November 2016
October 2016
September 2016
August 2016
July 2016
June 2016
May 2016
April 2016
March 2016
February 2016
January 2016
December 2015
November 2015
October 2015
September 2015
August 2015
July 2015
June 2015
May 2015
April 2015
March 2015
February 2015
January 2015
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
May 2013
A new model clinical trial agreement – the good, the bad and (in its current form) the ugly
26.06.2024
Clinical combinations: ever increasingly, two study products are better than one
24.05.2024
Competition Law Focus on Healthcare Markets Continues with Welcome (but Limited) CMA Guidance on Collaboration for Combination Therapies
06.12.2023
Failing faster using AI cannot be considered a success – A round-up of TechBio UK 2023 conference
13.11.2023
First CRISPR therapy seeks regulatory approval, but will it be able to avoid the pitfalls of other cell and gene therapies?
18.09.2023
Will we ever see a UKCA mark for medical devices?
28.03.2023
MDR and IVDR amending Regulation comes into force
21.03.2023
A brave new world for the regulation of medicines, devices and IVDs in the UK
16.03.2023
EU and UK reach new agreement on medicines regulation in Northern Ireland
07.03.2023
View more